Assertio to Be Acquired by Garda in Cash Deal

Assertio Therapeutics ( (ASRT) ) has issued an update.

On April 8, 2026, Assertio agreed to be acquired by Garda Therapeutics via an all-cash tender offer of $18 per share, valuing the equity at about $125.1 million, plus a non-tradeable contingent value right tied to future milestones from the Sprix product. The offer, unanimously approved by both boards, represents a premium of 34.6% to Assertio’s unaffected share price on March 20, 2026 and includes a 20-day window-shop period that allows the company to consider superior bids in exchange for a reduced breakup fee.

Concurrently on April 8, 2026, Assertio signed and closed an asset sale with Cosette Pharmaceuticals, divesting all non-Rolvedon assets, including Indocin, Sympazan, Sprix, Cambia, Zipsor and Otrexup, for $35 million upfront plus potential earnouts, with Sprix-related milestones to be passed to shareholders through the CVR. The Garda deal, expected to close in the second quarter of 2026 subject to customary conditions and a majority tender, will take Assertio private and delist its shares from Nasdaq, giving shareholders near-term cash value realization while leaving Rolvedon as the company’s sole remaining product around which Garda will build the post-merger business.

The most recent analyst rating on (ASRT) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Spark’s Take on ASRT Stock

According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.

The score is held back primarily by weak financial performance: shrinking multi-year revenue, ongoing losses, and a 2025 deterioration to negative operating/free cash flow. Technicals are supportive with a strong uptrend but are extremely overextended, raising near-term pullback risk. The earnings call adds moderate support via improving adjusted EBITDA guidance and Robodon-driven growth expectations, tempered by working-capital/cash pressure and legacy product erosion risk; valuation remains unattractive due to losses and no dividend.

To see Spark’s full report on ASRT stock, click here.

More about Assertio Therapeutics

Assertio Holdings, Inc. is a U.S. pharmaceutical company with commercial capabilities focused on marketing differentiated therapies primarily in the oncology market. The company has historically managed a portfolio of branded products, including pain and neurology franchises, but is increasingly centered on its remaining Rolvedon product following recent divestitures.

Average Trading Volume: 83,805

Technical Sentiment Signal: Hold

Current Market Cap: $118.7M

See more insights into ASRT stock on TipRanks’ Stock Analysis page.